282 related articles for article (PubMed ID: 33666363)
1. Persistence of CRISPR/Cas9 gene edited hematopoietic stem cells following transplantation: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Bailey AJM; Kirkham AM; Shorr R; Pineault N; Allan DS
Stem Cells Transl Med; 2021 Jul; 10(7):996-1007. PubMed ID: 33666363
[TBL] [Abstract][Full Text] [Related]
2. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
[TBL] [Abstract][Full Text] [Related]
3. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo culture resting time impacts transplantation outcomes of genome-edited human hematopoietic stem and progenitor cells in xenograft mouse models.
Demirci S; Khan MBN; Hinojosa G; Le A; Leonard A; Essawi K; Gudmundsdottir B; Liu X; Zeng J; Inam Z; Chu R; Uchida N; Araki D; London E; Butt H; Maitland SA; Bauer DE; Wolfe SA; Larochelle A; Tisdale JF
Cytotherapy; 2024 Jun; 26(6):641-648. PubMed ID: 38506770
[TBL] [Abstract][Full Text] [Related]
5. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.
Humbert O; Radtke S; Samuelson C; Carrillo RR; Perez AM; Reddy SS; Lux C; Pattabhi S; Schefter LE; Negre O; Lee CM; Bao G; Adair JE; Peterson CW; Rawlings DJ; Scharenberg AM; Kiem HP
Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366580
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.
Xu L; Yang H; Gao Y; Chen Z; Xie L; Liu Y; Liu Y; Wang X; Li H; Lai W; He Y; Yao A; Ma L; Shao Y; Zhang B; Wang C; Chen H; Deng H
Mol Ther; 2017 Aug; 25(8):1782-1789. PubMed ID: 28527722
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 Editing of the
Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
[TBL] [Abstract][Full Text] [Related]
9. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation for engraftment of CD34
Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
[TBL] [Abstract][Full Text] [Related]
11. A Genome Editing System for Therapeutical Targeting of Stem Cells.
Frati G; Miccio A
Methods Mol Biol; 2021; 2185():383-398. PubMed ID: 33165862
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Edited Stem Cell Transplantation for HIV-Related Gene Modification In Vivo: A Systematic Review.
Widjaya MA; Ju JC; Lee SD
Stem Cell Rev Rep; 2022 Jun; 18(5):1743-1755. PubMed ID: 35169967
[TBL] [Abstract][Full Text] [Related]
13. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
14. Automated Good Manufacturing Practice-Compatible CRISPR-Cas9 Editing of Hematopoietic Stem and Progenitor Cells for Clinical Treatment of β-Hemoglobinopathies.
Ureña-Bailén G; Block M; Grandi T; Aivazidou F; Quednau J; Krenz D; Daniel-Moreno A; Lamsfus-Calle A; Epting T; Handgretinger R; Wild S; Mezger M
CRISPR J; 2023 Feb; 6(1):5-16. PubMed ID: 36662546
[TBL] [Abstract][Full Text] [Related]
15. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
16. TRIAMF: A New Method for Delivery of Cas9 Ribonucleoprotein Complex to Human Hematopoietic Stem Cells.
Yen J; Fiorino M; Liu Y; Paula S; Clarkson S; Quinn L; Tschantz WR; Klock H; Guo N; Russ C; Yu VWC; Mickanin C; Stevenson SC; Lee C; Yang Y
Sci Rep; 2018 Nov; 8(1):16304. PubMed ID: 30389991
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs.
Crippa S; Conti A; Vavassori V; Ferrari S; Beretta S; Rivis S; Bosotti R; Scala S; Pirroni S; Jofra-Hernandez R; Santi L; Basso-Ricci L; Merelli I; Genovese P; Aiuti A; Naldini L; Di Micco R; Bernardo ME
Mol Ther; 2023 Jan; 31(1):230-248. PubMed ID: 35982622
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Cas9-AAV versus lentivector transduction for genome modification of X-linked severe combined immunodeficiency hematopoietic stem cells.
Brault J; Liu T; Liu S; Lawson A; Choi U; Kozhushko N; Bzhilyanskaya V; Pavel-Dinu M; Meis RJ; Eckhaus MA; Burkett SS; Bosticardo M; Kleinstiver BP; Notarangelo LD; Lazzarotto CR; Tsai SQ; Wu X; Dahl GA; Porteus MH; Malech HL; De Ravin SS
Front Immunol; 2022; 13():1067417. PubMed ID: 36685559
[TBL] [Abstract][Full Text] [Related]
19. Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones.
Smith RH; Chen YC; Seifuddin F; Hupalo D; Alba C; Reger R; Tian X; Araki D; Dalgard CL; Childs RW; Pirooznia M; Larochelle A
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33322084
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
